Are you Dr. Ohanian?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 44 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
1515 Holcombe Blvd
Houston, TX 77030Phone+1 713-792-7305Fax+1 713-792-4297- Is this information wrong?
Summary
- Dr. Maro Ohanian, DO is an oncologist in Houston, Texas. She is currently licensed to practice medicine in Texas, Florida, and Oklahoma. She is affiliated with University of Texas M.D. Anderson Cancer Center.
Education & Training
Texas A&M College of Medicine-Scott and White Medical Center (Temple)Fellowship, Hematology and Medical Oncology, 2009 - 2011
University of Texas Medical Branch HospitalsResidency, Internal Medicine, 2006 - 2009
Texas College of Osteopathic MedicineClass of 2006
Certifications & Licensure
FL State License 2021 - Present
TX State License 2009 - 2024
OK State License 2020 - 2021- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML Start of enrollment: 2016 May 01
- Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia Start of enrollment: 2017 Aug 09
- Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers Start of enrollment: 2018 Sep 19
- Join now to see all
Publications & Presentations
PubMed
- A phase 1/2 study of mini-hyper-CVD plus venetoclax in patients with relapsed/refractory acute lymphoblastic leukemia.Short, N., Jabbour, E., Jain, N., Senapati, J., Nasr, L., Haddad, F., Li, Z., Hsiao, Y., Yang, J., Pemmaraju, N., Ohanian, M., Wierda, W., Montalban-Bravo, G., Borthak...> ;Blood Advances. 2024 Feb 27
- KIT-mutated pediatric core-binding factor systemic mastocytosis-acute myeloid leukemia treated with avapritinib and decitabine.Garcia, M. B., Irtiza N Sheikh, Shaikha AlQahtani, C Cameron Yin, David McCall, Branko Cuglievan, Dristhi Ragoonanan, Jeremy S Connors, Amber Gibson, Cesar Nunez, Mich...> ;Pediatric Blood & Cancer. 2024 Apr 1
- 1 citationsResponse patterns and impact of MRD in patients with IDH1/2-mutated AML treated with venetoclax and hypomethylating agents.Danielle Hammond, Sanam Loghavi, Sa A Wang, Marina Y Konopleva, Tapan M Kadia, Naval G Daver, Maro Ohanian, Ghayas C Issa, Yesid Alvarado, Nicholas J Short, Koji Sasak...> ;Blood Cancer Journal. 2023 Sep 21
- Join now to see all
Authored Content
- Clinical Experience of Venetoclax Combinations for Relapsed/Refractory Myeloid MalignanciesOctober 2017
- The Combination of Quizartinib with Azacitidine or Low Dose Cytarabine Is Highly Active in Patients (Pts) with FLT3-ITD Mutated Myeloid Leukemias: Interim Report of a Phase I/II TrialOctober 2017
- Randomized Phase II Study of Guadecitabine (SGI-110) Based Regimens Comparing Guadecitabine 5 Days (SGI5), 10 Days (SGI10), 5 Days + Idarubicin (SGI5 + Ida), and 5 Days + Cladribine (SGI5 + Clad), in Previously Untreated Patients ≥ 70 Years with Acute Myeloid Leukemia (AML)–a Bayesian DesignOctober 2017
Press Mentions
HM43239 Demonstrates Durable Clinical Benefit in Acute Myeloid LeukemiaDecember 13th, 2021
Hospital Affiliations
University of Texas M.D. Anderson Cancer CenterHouston, Texas
